Home > Insider Trading > Filing (0001477932-23-005033)

Filing Details

Accession Number:: 0001477932-23-005033
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-07-06 08:27:57
Reporting Period:: 2022-09-30

Accepted Time:: 2023-07-06 08:27:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1443863	Biocorrx Inc.	BICX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1198613	J Joseph Galligan	2390 East Orangewood Avenue Suite 500 Anaheim CA 92806		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001	Acquisiton	2022-09-30	2,450	$0.00	40,931	No	4	A	Direct
Common Stock, Par Value $0.001	Acquisiton	2022-12-30	5,319	$0.00	46,250	No	4	A	Direct
Common Stock, Par Value $0.001	Acquisiton	2023-03-29	171,296	$1.75	217,546	No	4	P	Indirect	By Trust
Common Stock, Par Value $0.001	Acquisiton	2023-03-31	2,824	$0.00	220,370	No	4	A	Direct
Common Stock, Par Value $0.001	Acquisiton	2023-06-30	2,891	$0.00	223,261	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	A	Direct
No	4	P	Indirect	By Trust
No	4	A	Direct
No	4	A	Direct

Footnotes

These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04.
These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94.
These shares were issued to The J and R Galligan Revocable Trust, managed by Mr. Joseph M. Galligan (the "Galligan Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Galligan Trust dated March 29 2023, and paid for on March 30, 2023. The Reporting Person may be deemed to have investment power over the Galligan Trust.
These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77.
These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73.